Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results